Patients with NSTEACS and elevated troponin but without obstructive CAD, while having low rates of subsequent MI, are still at considerable risk for 1-year mortality from cardiac and non-cardiac causes. Further data regarding the underlying etiologies of death in this high-risk cohort will be presented.
TCT-389 Are Adverse Events Following an Invasive Strategy in Patients with Non STSegment Elevation Acute Coronary Syndromes (NSTEACS) More Frequent at US Sites vs Non US Sites (OUS)? Analysis from the ACUITY Trial
Background: Previous studies suggested worse outcomes with primary PCI for STEMI at US vs OUS sites, but there are little data in pts with NSTEACS. Methods: ACUITY randomized 13,819 NSTEACS pts in 17 countries to an early invasive approach with 1 of 3 strategies: 1) heparin plus GPI, 2) bivalirudin (Biv) plus GPI, or 3) Biv alone. Results: US pts were heavier, had more HTN, DM, prior MI, prior CABG and anemia. OUS pts were older, had more renal insufficiency and more positive cardiac markers. US pts were more often managed with medical therapy and less often with PCI but had more DES use (83% vs 37%, p<0.0001). US pts received aspirin, statins and beta blockers more often at admission, but received thienopyridines less often preangiography and at discharge. At 1 yr US pts had lower mortality and lower TVR but more MI. Bleeding was similar at 30 days. After adjusting for baseline risk, US pts had more MI but lower TVR with no difference in mortality or MACE. ACUITY 1 Year Outcomes: US vs OUS Conclusion: US pts with NSTEACS had higher rates of MI but lower rates of TVR and no differences in adjusted mortality and bleeding. Lower TVR rates may be related to greater DES use. Higher rates of MI at US sites may be due to unmeasured confounders, differences in the threshold for event reporting, or valid differences in systems of care and treatment which may impact outcomes.
PCI Outcomes
(Abstract nos 390 -406) While a large national analysis demonstrated low overall rates of inappropriate revascularization, variability exists among institutions. We sought to determine whether use of a prospective AUC assessment tool used at the time of procedure would improve rates of appropriate revascularization. Methods: A form was designed to be used at the time of diagnostic coronary angiography. The form includes five key factors: 1) classification of angina severity, 2) level of risk based on non-invasive stress testing, 3) presence of other high risk markers, 4) number of anti-anginal medications, and 5) coronary anatomy. The first four to be considered prior to starting the angiogram, so that real-time decision-making could be made about the appropriateness of revascularization once the coronary anatomy was known. Results: Since initiation of the AUC tool in March 2011 at our cardiac center, 216 patients underwent coronary revascularization. For these cases, overall rates of appropriate (A), uncertain (U), and inappropriate (I) revascularization were 89%, 9%, and 2%, respectively. Patients with acute coronary syndrome (ACS) (68%) had A, U, and I scores of 94%, 4% and 2%, respectively. Among those with stable ischemic heart disease (SIHD), 47% had an intermediate or high-risk noninvasive stress test. There was infrequent use of >1 anti-anginal medication in all patients (48% in ACS versus 37% in SIHD). Compared to same facility retrospective analysis from the preceding 18 months, inappropriate rates after implementation of the AUC tool dropped from 3% to 2%. Conclusion: Symptoms, angina class and stress test findings predominantly drive revascularization decisions. An unacceptably high number of patients with low risk stress tests or suboptimal anti-anginal therapy undergo revascularization. Routine use of our assessment tool allows the appropriateness status to be determined at the time of procedure and results in a lower rate of inappropriate revascularization.
